Press Releases EyePoint Pharmaceuticals, Inc.

Equities

EYPT

US30233G2093

Real-time Estimate Cboe BZX Other stock markets 11:58:30 2024-06-06 am EDT			5-day change	1st Jan Change
9.46 ^USD	-3.37%		-11.44%	-58.81%

Jun. 04	JPMorgan Adjusts EyePoint Pharmaceuticals Price Target to $32 From $35, Maintains Overweight Rating	MT
May. 08	Baird Adjusts Price Target on EyePoint Pharmaceuticals to $38 From $46, Keeps Outperform Rating	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

EyePoint Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference	Jun. 05	AQ
EyePoint Pharmaceuticals : Investor Presentation May 2024	May. 28	PU
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	May. 16	AQ
EyePoint Pharmaceuticals: Q1 Earnings Snapshot	May. 08	AQ
EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Developments	May. 08	AQ
EyePoint Pharmaceuticals : PAVIA Topline Data Conference Call Presentation	May. 06	PU
EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic Retinopathy	May. 06	AQ
EyePoint Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(4)	Apr. 17	AQ
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	Apr. 16	AQ
EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists	Apr. 02	AQ
EyePoint Pharmaceuticals : Investor Presentation March 2024	Mar. 22	PU
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	Mar. 18	AQ
EyePoint Pharmaceuticals: Q4 Earnings Snapshot	Mar. 07	AQ
EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments	Mar. 07	AQ
EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer	Mar. 04	AQ
EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on March 7, 2024	Feb. 29	AQ
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences	Feb. 27	AQ
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	Feb. 16	AQ
EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration	Feb. 05	AQ
EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration	Feb. 03	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases EyePoint Pharmaceuticals, Inc.

Equities

EYPT

US30233G2093

Press Releases

Filters